

Global Markets for Generic Drugs

Market Research Report | 2024-01-15 | 126 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

The report discusses the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets. The report covers small molecule drugs and biosimilars. It includes market drivers and challenges in the generic drug industry. The competitive landscape includes generic drug sales of key competitors and their ranking in the market. It also covers the emerging trends in the generic drugs industry.

By geographical region, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes countries such as the U.S., Canada and Mexico; Europe includes Germany, U.K., Italy, and Rest of Europe; Asia-Pacific includes China, India, Japan, and Rest of Asia-Pacific. The estimated values used are based on drug manufacturers' total revenues.

Report Includes:

- 37 data tables and 39 additional tables
- An overview of the global markets for generic (pharmaceutical) drugs
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimate of the market size and revenue forecast of the market for generic drugs, and corresponding market share analysis based on molecule type and geographic region
- Evaluation of the current and future market potential of generic drugs, as well as the major generics, regulatory landscape and patent cliff within the biopharmaceutical industry

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Discussion of the major market drivers, opportunities and challenges, emerging technologies, and regulations
- Data and market value analyses for the U.S., Canada, Mexico, Germany, the U.K., Italy, China, India and Japan
- Overview of the sustainability trends and factors in the market for generic drugs, with emphasis on consumer attitudes, ESG scores, case studies and the ESG practices of leading companies
- Analysis of the pipeline for new generic drugs and their impact on the growth of the overall biopharmaceutical products market
- Patent review and analysis of key patent grants
- An analysis of the industry structure, including company market shares, recent M&A activity, and venture funding
- Analysis of the top market players, their global rankings, recent developments, key financials and segmental revenues, and product portfolios
- Profiles of the leading market players

Executive Summary

Summary:

The global market for generic drugs was valued at \$REDACTED billion in 2022. The market is forecast to grow from \$REDACTED billion in 2023 at a compound annual growth rate (CAGR) of REDACTED% to reach approximately \$REDACTED billion by the end of 2028.

The increasing patent cliffs and exclusivities, favorable regulatory policies, and positive changes in prescription patterns are responsible for market growth.

This report segments the global market by molecule type and region. The market is categorized into small-molecule drugs and biosimilars based on molecule type. The small molecule drugs segment, which held the largest share in 2022, is expected to grow at a REDACTED% CAGR during the forecast period. This segment's large share is attributed to the growing medical needs of chronically ill patients. The biosimilars segment is growing at a higher CAGR, REDACTED%, during the forecast period. The increasing prevalence of cancer and immunological diseases drives the need for low-cost biosimilars.

Some companies in this market include Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Viatris Inc., Sun Pharmaceutical Ltd., and Fresenius Kabi.

Table of Contents:

Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in this Update?
Research Methodology
Information Sources
Regional Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market Overview
Introduction

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Adequate Market Size
Patent-Expired Therapies
Older Products Still Used
Long-Term Use
Straightforward Production Technology
Drugs Used in Primary Care
Biosimilars
Chapter 4 Market Dynamics
Market Drivers
Increasing Patent Cliffs and Loss of Exclusivities
Favorable Healthcare Policies
Changing Physician Attitudes
Market Challenges
Pricing Pressures and Low Profit Margins
Patent Extension Strategies of Innovator Companies
Chapter 5 Market Breakdown by Molecule Type
Global Market for Generic Drugs
Global Generic Drugs Market, by Molecule Type
Small Molecule Generics
Biosimilars
Chapter 6 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World
Chapter 7 Sustainability: An ESG Perspective
Introduction to ESG
Sustainability in the Generic Drugs Industry: An ESG Perspective
Key ESG Issues
Environmental Performance of Key Generic Drug Companies
Social Performance of Key Generic Drug Companies
Governance Performance of Key Generic Drug Companies
Case Study
Concluding Remarks from BCC

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Chapter 8 Emerging Trends and Developments
Key Trends in the Market
Collaborations for R&D
Rise of Complex Generics in Immunology and Oncology
Improving Portfolio Efficiency
Focus on Emerging Markets
Chapter 9 Regulatory Landscape
Regulatory Overview
U.S.
Evolving Situation in the U.S.
European Union
Japan
Regulation of Biosimilars
EU Provisions
Authorized Generic Drugs
Chapter 10 Competitive Landscape
Competitive Landscape
M&A Analysis
Chapter 11 Company Profiles
ASPEN PHARMACARE
AUROBINDO PHARMA
CIPLA INC.
DR. REDDY'S LABORATORIES LTD.
FRESENIUS KABI
LUPIN LTD.
SANDOZ
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.

Global Markets for Generic Drugs

Market Research Report | 2024-01-15 | 126 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-06"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com